Fig. 2From: PR status is a more decisive factor in efficacy of adding pertuzumab into neoadjuvant therapy for HER2-positive and lymph node-positive breast cancer than ER status: a real-world retrospective study in ChinaThe ROC curves. a The ROC curve of anti-HER2 therapy on predicting pCR in different cohorts. b The ROC curve of ER and PR status on predicting pCR in group HPBack to article page